Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when STOK files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsStoke Therapeutics shareholders approve routine annual meeting matters, 27% oppose exec pay
Filed June 4, 2026 · Period ending June 3, 2026 · ~1 min read
Key Changes
-
medium
Shareholders approved executive compensation on advisory vote with 73% support, but 27% voted against, suggesting notable concern about pay levels or structure disclosed in April proxy.
Item 5.07 verify on EDGAR → -
low
Three Class I directors elected to three-year terms through 2029: G. Clare Kahn, Adrian Krainer, and Julie Anne Smith, with varying vote margins.
Item 5.07 verify on EDGAR → -
low
Ernst & Young ratified as independent auditor for fiscal 2026 with over 99% approval, continuing existing audit relationship.
Item 5.07 verify on EDGAR →
Summary
Stoke Therapeutics held its 2026 Annual Meeting on June 3, completing standard corporate governance matters. All three director nominees were elected and the auditor was ratified with overwhelming support.
However, the executive compensation vote revealed a split among shareholders: while the non-binding say-on-pay proposal passed with 73% approval, more than one in four shareholders voted against management's compensation practices as detailed in the April proxy statement. For retail investors, this is primarily a procedural filing with no immediate business impact.
The elevated opposition to executive pay (27%) is worth noting but not alarming—it suggests some institutional investors may have concerns about compensation structure or levels relative to company performance. Investors should review the proxy statement filed April 22 to understand what triggered the dissent. Watch for any management response or compensation committee adjustments in next year's proxy materials.
Section-by-Section Diff
Event · Item 5.07 — Submission of Matters to a Vote of Security Holders
Stoke Therapeutics held its 2026 Annual Meeting, electing three Class I directors, ratifying Ernst & Young as auditor, and approving executive compensation.
Added in current filing · verify on EDGAR →
Approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers as disclosed in the Company’s definitive proxy statement filed with the U.S. Securities and Exchange Commission on April 22, 2026
Shareholders approved executive compensation on a non-binding advisory basis with 36,436,275 votes for and 13,565,293 votes against. While the vote passed, the 27% opposition suggests some shareholder concern about executive pay levels or structure.
Show 2 minor / wording changes
Added in current filing · verify on EDGAR →
Election of three Class I directors, G. Clare Kahn, Ph.D., Adrian Krainer, Ph.D. and Julie Anne Smith, each to serve a three-year term, which will expire upon the earlier of the 2029 annual meeting of stockholders or until such time as their respective successors have been duly elected and qualified or their earlier resignation or removal
Three Class I directors were elected at the 2026 Annual Meeting to serve three-year terms expiring in 2029. G. Clare Kahn received 49,722,339 votes for, Adrian Krainer received 36,531,612 votes for, and Julie Anne Smith received 43,500,649 votes for. All three directors were elected despite varying levels of withheld votes.
Added in current filing · verify on EDGAR →
Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026
Shareholders ratified Ernst & Young LLP as the independent auditor for fiscal year 2026 with 55,121,163 votes for, 2,036 votes against, and 51,714 abstentions. This is a routine annual vote confirming the audit committee's selection.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 5, 2026 · How we verify